Skip to main content
Top
Published in: Japanese Journal of Ophthalmology 3/2015

01-05-2015 | Clinical Investigation

Incidence and clinical features of recurrent Vogt-Koyanagi-Harada disease in Japanese individuals

Authors: Chiharu Iwahashi, Kensuke Okuno, Noriyasu Hashida, Kei Nakai, Nobuyuki Ohguro, Kohji Nishida

Published in: Japanese Journal of Ophthalmology | Issue 3/2015

Login to get access

Abstract

Purpose

Our aim was to determine the recurrence rate of inflammation in Vogt-Koyanagi-Harada (VKH) disease and to describe its clinical features.

Methods

We retrospectively evaluated patients diagnosed as having VKH disease with exudative retinal detachment at the Osaka University Hospital or the Japanese Community Healthcare Organization, Osaka Hospital, between 1998 and 2012. All patients received high-dose corticosteroid therapy as the initial treatment and were followed for at least 6 months. Demographic data, including age, sex, visual acuity (VA) levels at initial presentation and at 1 year after initial therapy, treatment received, and recurrent episodes were reviewed.

Results

Fifty-five consecutive patients with VKH disease were identified (36 women; mean age 38.6 ± 10.4 years). Fourteen patients (25.5 %) had recurrent inflammation, which manifested as posterior uveitis in eight and as anterior uveitis in six of the patients. Recurrent posterior segment inflammation was more likely to develop in patients whose VA at initial presentation was poor (P = 0.039) and in whom orally administered corticosteroid was tapered rapidly (to 30 mg within 3 weeks or less, to 20 mg within 2 months or less, and to 10 mg within 3 months or less) (P = 0.006, P = 0.066, and P = 0.041, respectively).

Conclusions

About 25 % of patients with VKH disease had recurrent inflammation. Poor initial VA and rapid tapering of the corticosteroid were associated with posterior recurrence.
Literature
1.
go back to reference Ohguro N, Sonoda KH, Takeuchi M, Matsumura M, Mochizuki M. A prospective multi-center epidemiologic survey of uveitis in Japan: a 2009 survey. Jpn J Ophthalmol. 2012;56:432–5.CrossRefPubMed Ohguro N, Sonoda KH, Takeuchi M, Matsumura M, Mochizuki M. A prospective multi-center epidemiologic survey of uveitis in Japan: a 2009 survey. Jpn J Ophthalmol. 2012;56:432–5.CrossRefPubMed
2.
go back to reference Yamaki K, Gocho K, Hayakawa K, Kondo I, Sakuragi S. Tyrosine family proteins are antigens specific to Vogt-Koyanagi-Harada disease. J Immunol. 2000;165:7323–9.CrossRefPubMed Yamaki K, Gocho K, Hayakawa K, Kondo I, Sakuragi S. Tyrosine family proteins are antigens specific to Vogt-Koyanagi-Harada disease. J Immunol. 2000;165:7323–9.CrossRefPubMed
3.
go back to reference Yamaki K, Kondo I, Nakamura H, Miyano M, Konno S, Sakuragi S. Ocular and extraocular inflammation induced by immunization of tyrosinase related protein 1 and 2 in Lewis rats. Exp Eye Res. 2000;71:361–9.CrossRefPubMed Yamaki K, Kondo I, Nakamura H, Miyano M, Konno S, Sakuragi S. Ocular and extraocular inflammation induced by immunization of tyrosinase related protein 1 and 2 in Lewis rats. Exp Eye Res. 2000;71:361–9.CrossRefPubMed
4.
6.
go back to reference Read RW, Rechodouni A, Butani N, Johnston R, Labree LD, Smith RE, et al. Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2001;31:599–606.CrossRef Read RW, Rechodouni A, Butani N, Johnston R, Labree LD, Smith RE, et al. Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2001;31:599–606.CrossRef
7.
go back to reference Shindo Y, Inoko H, Yamamoto T, Ohno S. HLA-DRB1 typing of Vogt-Koyanagi-Harada’s disease by PCR-RFLP and the strong association with DRB1*0405 and DRB1*0410. Br J Ophthalmol. 1994;78:223–6.CrossRefPubMedCentralPubMed Shindo Y, Inoko H, Yamamoto T, Ohno S. HLA-DRB1 typing of Vogt-Koyanagi-Harada’s disease by PCR-RFLP and the strong association with DRB1*0405 and DRB1*0410. Br J Ophthalmol. 1994;78:223–6.CrossRefPubMedCentralPubMed
8.
go back to reference Islam SM, Numaga J, Matsuki K, Fujino Y, Maeda H, Masuda K. Influence of HLA-DRB1 gene variation on the clinical course of Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 1994;35:752–6.PubMed Islam SM, Numaga J, Matsuki K, Fujino Y, Maeda H, Masuda K. Influence of HLA-DRB1 gene variation on the clinical course of Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 1994;35:752–6.PubMed
9.
go back to reference Weisz JM, Holland GN, Roer LN, Park MS, Yuge AJ, Moorthy RS, et al. Association between Vogt-Koyanagi-Harada syndrome and HLA-DR1 and -DR4 in Hispanic patients living in southern California. Ophthalmology. 1995;102:1012–5.CrossRefPubMed Weisz JM, Holland GN, Roer LN, Park MS, Yuge AJ, Moorthy RS, et al. Association between Vogt-Koyanagi-Harada syndrome and HLA-DR1 and -DR4 in Hispanic patients living in southern California. Ophthalmology. 1995;102:1012–5.CrossRefPubMed
10.
go back to reference Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131:647–52.CrossRefPubMed Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131:647–52.CrossRefPubMed
11.
go back to reference Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology. 2006;113:2317–23.CrossRefPubMed Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology. 2006;113:2317–23.CrossRefPubMed
12.
go back to reference Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Pohthalmol. 2008;126:1191–201.CrossRef Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Pohthalmol. 2008;126:1191–201.CrossRef
13.
go back to reference Sachdev N, Gupta V, Gupta A, Singh R. Posterior segment recurrences in Vogt-Koyanagi-Harada disease. Int Ophthalmol. 2008;28:339–45.CrossRefPubMed Sachdev N, Gupta V, Gupta A, Singh R. Posterior segment recurrences in Vogt-Koyanagi-Harada disease. Int Ophthalmol. 2008;28:339–45.CrossRefPubMed
14.
go back to reference Lai TY, Chan RP, Chan CK, Lam DS. Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease. Eye. 2009;23:543–8.CrossRefPubMed Lai TY, Chan RP, Chan CK, Lam DS. Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease. Eye. 2009;23:543–8.CrossRefPubMed
15.
go back to reference Rubsamen PE, Gass JD. Vogt-Koyanagi-Harada syndrome: clinical course, therapy, and long-term visual outcome. Arch Ophthalmol. 1991;109:682–7.CrossRefPubMed Rubsamen PE, Gass JD. Vogt-Koyanagi-Harada syndrome: clinical course, therapy, and long-term visual outcome. Arch Ophthalmol. 1991;109:682–7.CrossRefPubMed
16.
go back to reference Al-Kharashi AS, Aldibhi H, Al-Fraykh H, Kangave D. Abu El-Asrar AM. Prognostic factors in Vogt-Koyanagi-Harada disease. Int Ophthalmol. 2007;27:201–10.CrossRefPubMed Al-Kharashi AS, Aldibhi H, Al-Fraykh H, Kangave D. Abu El-Asrar AM. Prognostic factors in Vogt-Koyanagi-Harada disease. Int Ophthalmol. 2007;27:201–10.CrossRefPubMed
17.
go back to reference Errera MH, Fardeau C, Cohen D, Navarro A, Gaudric A, Bodaghi B, et al. Effect of the duration of immunomodulatory therapy on the clinical features of recurrent episodes in Vogt-Koyanagi-Harada disease. Acta Ophthalmol. 2011;89:357–66.CrossRef Errera MH, Fardeau C, Cohen D, Navarro A, Gaudric A, Bodaghi B, et al. Effect of the duration of immunomodulatory therapy on the clinical features of recurrent episodes in Vogt-Koyanagi-Harada disease. Acta Ophthalmol. 2011;89:357–66.CrossRef
18.
go back to reference Bacsal K, Wen DS, Chee SP. Concomitant choroidal inflammation during anterior segment recurrence in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2008;145:480–6.CrossRefPubMed Bacsal K, Wen DS, Chee SP. Concomitant choroidal inflammation during anterior segment recurrence in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2008;145:480–6.CrossRefPubMed
19.
go back to reference Taylor S, Lightman S. Recurrent anterior uveitis in patients with Vogt-Koyanagi-Harada syndrome. Arch Ophthalmol. 2004;122:922–3.CrossRefPubMed Taylor S, Lightman S. Recurrent anterior uveitis in patients with Vogt-Koyanagi-Harada syndrome. Arch Ophthalmol. 2004;122:922–3.CrossRefPubMed
20.
go back to reference Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513.CrossRefPubMed Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513.CrossRefPubMed
21.
go back to reference Kondo Y, Fukuda K, Suzuki K, Nishida T. Chronic noninfectious uveitis associated with Vogt-Koyanagi-Harada disease treated with low-dose weekly systemic methotrexate. Jpn J Ophthalmol. 2012;56:104–6.CrossRefPubMed Kondo Y, Fukuda K, Suzuki K, Nishida T. Chronic noninfectious uveitis associated with Vogt-Koyanagi-Harada disease treated with low-dose weekly systemic methotrexate. Jpn J Ophthalmol. 2012;56:104–6.CrossRefPubMed
22.
go back to reference Liu X, Yang P, Lin X, Ren X, Zhou H, Huang X, et al. Inhibitory effect of cyclosporin A and corticosteroids on the production of IFN-gamma and IL-17 by T cells in Vogt-Koyanagi-Harada syndrome. Clin Immunol. 2009;131:333–42.CrossRefPubMed Liu X, Yang P, Lin X, Ren X, Zhou H, Huang X, et al. Inhibitory effect of cyclosporin A and corticosteroids on the production of IFN-gamma and IL-17 by T cells in Vogt-Koyanagi-Harada syndrome. Clin Immunol. 2009;131:333–42.CrossRefPubMed
23.
go back to reference Nakao K, Abematsu N, Mizushima Y, Sakamoto T. Optic disc swelling in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 2012;53:1917–22.CrossRefPubMed Nakao K, Abematsu N, Mizushima Y, Sakamoto T. Optic disc swelling in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 2012;53:1917–22.CrossRefPubMed
Metadata
Title
Incidence and clinical features of recurrent Vogt-Koyanagi-Harada disease in Japanese individuals
Authors
Chiharu Iwahashi
Kensuke Okuno
Noriyasu Hashida
Kei Nakai
Nobuyuki Ohguro
Kohji Nishida
Publication date
01-05-2015
Publisher
Springer Japan
Published in
Japanese Journal of Ophthalmology / Issue 3/2015
Print ISSN: 0021-5155
Electronic ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-015-0377-1

Other articles of this Issue 3/2015

Japanese Journal of Ophthalmology 3/2015 Go to the issue